The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors(PRaG9.0)
Latest Information Update: 03 Nov 2023
Price :
$35 *
At a glance
- Drugs Disitamab vedotin (Primary) ; Granulocyte macrophage colony stimulating factor (Primary) ; Thymopentin (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms PRaG9.0
- 03 Nov 2023 New trial record